July 2009
BioWorld Today;7/15/2009, Vol. 20 Issue 134, p6
This section offers news briefs related to several clinical trials. A Phase I/II trial with CF102 for the treatment of hepatitis C virus by Can-Fite BioPharma of Petach Tikva, Israel will begin to enroll patients. Enrollment for the first of two ongoing blinded, placebo-controlled, multicenter, parallel group studies of AZX100 by Capstone Therapeutics of Tempe, Arizona has been completed. A Phase I study has been initiated by Keryx Biopharmaceuticals Inc. to evaluate the KRX-0401 anticancer agent.


Related Articles

  • Dry-Eye Phase III Trial Enrolled, OphthaliX 'Wets' Oral Appetite. Osborne, Randy // BioWorld Today;3/19/2013, Vol. 24 Issue 52, p1 

    The article reports that OphthaliX has tackled its first-in-class A3 adenosine receptor agonist CF101 in a 24-week, 236-patient placebo-controlled Phase III trial. It states that serendipity data provided by patients in a rheumatoid arthritis (RA) trial with CF101 led to dry-eye syndrome (DES)...

  • CAN-FITE BIOPHARMA INITIATES CF102 TRIAL FOR LIVER CANCER.  // Worldwide Biotech;May2009, Vol. 21 Issue 5, p8 

    This article reports on the plan of Can-Fite BioPharma of Israel to conduct a I/II clinical trial with CF102 for the treatment of liver cancer in 2009. Can-Fite announced that it will start enrolling patients for the clinical trial. The company will investigate the safety and efficacy of CF102...

  • Other News To Note.  // BioWorld International;9/4/2013, Vol. 18 Issue 36, p9 

    This section offers news briefs. Israeli biopharmaceutical company Can-Fite Biopharma Ltd. will begin Phase 2 study of cancer drug CF102 for primary liver cancer. Pharmaceutical company Dezima Pharma BV of Naarden initiated a Phase 2b dose-ranging study of DEZ-001 to study effects of...

  • Keryx Set to 'Pound Pavement' with SPA for Perifosine Study. Osborne, Randy // BioWorld Today;8/4/2009, Vol. 20 Issue 148, p1 

    The article reports on a prediction that Keryx Biopharmaceuticals Inc. will engage in partnership talks after the disclosure on August 3, 2009 of the special protocol assessment (SPA) for a trial with the company's multiple myeloma (MM) drug perifosine. The drug, which is licensed to Keryx in...

  • Can-Fite's CF101 delivers can-do performance in RA. Powers, Marie // BioWorld Today;12/24/2013, Vol. 24 Issue 246, p1 

    The article reports that Can-Fite Biopharma Ltd. impressed investors with results from its Phase IIb trial results of CF101 drug product as a monotherapy for rheumatoid arthritis (RA). It says that the study demonstrated statistically significant quality compared to placebo in reducing RA signs...

  • CLINIC ROUNDUP.  // BioWorld Today;5/6/2008, Vol. 19 Issue 88, p4 

    This section offers news briefs on the pharmaceutical industry. Anesiva Inc. has announced the publication of data from a Phase III trial of Zingo powder intradermal injection in "Journal Pediatrics." Can-Fite BioPharma has successfully completed a Phase I trial with its second pipeline drug,...

  • CLINIC ROUNDUP.  // BioWorld Today;4/2/2010, Vol. 21 Issue 63, p7 

    This section offers news briefs on clinical trials including the completion by Can-Fite BioPharma Ltd. of patient recruitment for its Phase 1/II trial of CF102 in the treatment of patients with advanced hepatocellular carcinoma and the initiation by Symphogen A/S of a Phase I/II trial in the U.S.

  • CLINIC ROUNDUP.  // BioWorld Today;5/25/2010, Vol. 21 Issue 100, p7 

    This section offers news briefs on clinical trials in the biopharmaceutical industry as of May 25, 2010. The Israeli Ministry of Health has given its approval for the Phase II trial of orally administered CF101 in glaucoma by Can-Fite BioPharma Ltd. The Swedish Medical Products Agency has...

  • CLINIC ROUNDUP.  // BioWorld Today;4/17/2009, Vol. 20 Issue 73, p5 

    This section offers news briefs on clinical trials within the biotechnology industry. The Israel Ministry of Health and Rabin MC Ethics Committee have approved the Phase I/II trial of Can-Fite BioPharma for CF102 for the treatment of liver cancer. Diamyd Medical AB plans to cut costs by...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics